Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals

Antiviral Therapy

Volumn 19, Issue 3, 2014, Pages 309-317

  Gillis, Jennifer ^a   Smieja, Marek ^b   Cescon, Angela ^c   Rourke, Sean B ^d,e,f   Burchell, Ann N ^d,e   Cooper, Curtis ^g   Raboud, Janet M ^a,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ONTARIO HIV TREATMENT NETWORK   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; VIRUS RNA;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INCOME; INTRAVENOUS DRUG ABUSE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SUDDEN CARDIAC DEATH; TRANSLUMINAL CORONARY ANGIOPLASTY; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MORTALITY; PHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; TIME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CARDIOVASCULAR DISEASES; COINFECTION; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SURVIVAL ANALYSIS; TIME FACTORS; VIRAL LOAD;

EID: 84902658836     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2724     Document Type: Article

References (27)

1. Kamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS 2005; 19:641-652.
2. Palella FJ, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS 2011; 6:266-271.
3. Friis-Møller N, Smieja M, Klein D. Antiretroviral therapy as a cardiovascular disease risk factor: fact or fiction? A review of clinical and surrogate outcome studies. Curr Opin HIV AIDS 2008; 3:220-225.
4. Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009; 9:37-42.
5. Koziel MJ, Peters MG. Viral hepatitis and HIV infection. N Engl J Med 2007; 356:1445-1454.
6. Bedimo R, Ghurani R, Nsuami M, et al. Lipid abnormalities in HIV/hepatitis C virus-coinfected patients. HIV Med 2006; 7:530-536.
7. Polgreen PM, Fultz SL, Justice AC, et al. Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV Med 2004; 5:144-150.
8. Cooper CL, Mills E, Angel JB. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS 2007; 21:71-76.
9. Diong C, Raboud J, Li M, Cooper C. HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia. HIV Med 2011; 12:403-411.
10. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Defic Syndr 2001; 27:245-250.
11. de Larrañaga GF, Wingeyer SD, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis 2006; 25:98-103.
12. Sosner P, Wangermez M, Chagneau-Derrode C, Le Moal G, Silvain C. Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. Atherosclerosis 2012; 222:274-277.
13. Tien PC, Schneider MF, Cole SR, et al. Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study. AIDS 2009; 23:1781-1784.
14. Masá M, Padilla S, Robledano C, Ramos JM, Gutierrez F. Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study. BMC Infect Dis 2011; 11:265-272.
15. Freiberg MS, Cheng DM, Kraemer KL, Saitz R, Kuller LH, Samet JH. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS 2007; 21:193-197.
16. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010; 11:462-468.
17. The Data Collection on Adverse Events of Anti-HIV Drugs D:A:D) Study Group. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther 2010; 15:1077-1086.
18. Rourke SB, Gardner S, Burchell AN, et al. Cohort profile: The Ontario HIV Treatment Network Cohort Study (OCS). Int J Epidemiol 2013; 42:402-411.
19. Pintilie M. Competing risks: a practical perspective. 1st ed. Chichester: John Wiley & Sons 2006.
20. Newgard CD, Haukoos JS. Advanced statistics: missing data in clinical research - part 2: multiple imputation. Acad Emerg Med 2007; 14:669-678.
21. Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 2012; 59:1891-1896.
22. Butler B, Rubin G, Lawrance A, Batey R, Bell J. Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction. Drug Alcohol Rev. 2011; 30:173-180.
23. Gamouras GA, Monir G, Plunkitt K, Gursoy S, Dreifus LS. Cocaine abuse: repolarization abnormalities and ventricular arrhythmias. Am J Med Sci 2000; 320:9-12.
24. Worm SW, Kamara DA, Reiss P, et al. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. J Infect Dis 2012; 205:535-539.
25. Vallecillo G, Mojal S, Roquer A, et al. Risk of QTc prolongation in a cohort of opioid-dependent HIV-infected patients on methadone maintenance therapy. Clin Infect Dis 2013; 57:1189-1194.
26. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008; 121:66-71.
27. Beyersmann J, Wolkewitz M, Schumacher M. The impact of time-dependent bias in proportional hazards modelling. Stat Med 2008; 27:6439-6454.